These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38857952)

  • 41. Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis.
    Winterstein AG; Eworuke E; Xu D; Schuler P
    Pediatr Pulmonol; 2013 Sep; 48(9):874-84. PubMed ID: 23139089
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Respiratory syncytial virus: how, why and what to do.
    Rodriguez R; Ramilo O
    J Infect; 2014 Jan; 68 Suppl 1():S115-8. PubMed ID: 24171820
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of the timing of initial prophylactic palivizumab dosing on hospitalization of neonates for respiratory syncytial virus.
    Ohler KH; Pham JT
    Am J Health Syst Pharm; 2013 Aug; 70(15):1342-6. PubMed ID: 23867491
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Balanced on the Biggest Wave: Nirsevimab for Newborns.
    McPherson C; Lockowitz CR; Newland JG
    Neonatal Netw; 2024 Apr; 43(2):105-115. PubMed ID: 38599778
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age.
    Cieslak CM
    Nurs Womens Health; 2024 Feb; 28(1):75-79. PubMed ID: 38070539
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.
    Sun M; Lai H; Na F; Li S; Qiu X; Tian J; Zhang Z; Ge L
    JAMA Netw Open; 2023 Feb; 6(2):e230023. PubMed ID: 36800182
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention.
    Manzoni P; Paes B; Resch B; Carbonell-Estrany X; Bont L
    Early Hum Dev; 2012 May; 88 Suppl 2():S34-41. PubMed ID: 22633511
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use.
    Prais D; Schonfeld T; Amir J;
    Pediatrics; 2003 Sep; 112(3 Pt 1):548-52. PubMed ID: 12949282
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain.
    Figueras-Aloy J; Carbonell-Estrany X; Quero J;
    Pediatr Infect Dis J; 2004 Sep; 23(9):815-20. PubMed ID: 15361718
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Impact of a targeted educational intervention on respiratory syncytial virus bronchiolitis prevention in full-term and preterm infants].
    Bernard L; Lecomte B; Pereira B; Proux A; Boyer A; Sautou V
    Arch Pediatr; 2015 Feb; 22(2):146-53. PubMed ID: 25534557
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hospital Admission Trends for Bronchiolitis in Scotland, 2001-2016: A National Retrospective Observational Study.
    Chung A; Reeves RM; Nair H; Campbell H;
    J Infect Dis; 2020 Oct; 222(Suppl 7):S592-S598. PubMed ID: 32794556
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain.
    Pérez Martín JJ; Zornoza Moreno M
    Hum Vaccin Immunother; 2024 Dec; 20(1):2365804. PubMed ID: 39137331
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.
    Diehl JL; Daw JR; Coley KC; Rayburg R
    J Manag Care Pharm; 2010; 16(1):23-31. PubMed ID: 20044844
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg.
    Ernst C; Bejko D; Gaasch L; Hannelas E; Kahn I; Pierron C; Del Lero N; Schalbar C; Do Carmo E; Kohnen M; Andlauer E; Hublart P; Masi S; de la Fuente Garcia I; Vergison A; Mossong J
    Euro Surveill; 2024 Jan; 29(4):. PubMed ID: 38275017
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in Taiwan.
    Chi H; Hsu CH; Chang JH; Chiu NC; Hung HY; Kao HA; Weng LC; Huang FY; Chiu YY; Chang LY; Huang LM
    PLoS One; 2014; 9(6):e100981. PubMed ID: 24971565
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database.
    Law BJ; Wang EE; MacDonald N; McDonald J; Dobson S; Boucher F; Langley J; Robinson J; Mitchell I; Stephens D
    Pediatrics; 1997 Mar; 99(3):E7. PubMed ID: 9099772
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness of nirsevimab against RSV-bronchiolitis in paediatric ambulatory care: a test-negative case-control study.
    Lassoued Y; Levy C; Werner A; Assad Z; Bechet S; Frandji B; Batard C; Sellam A; Cahn-Sellem F; Fafi I; Lenglart L; Aupiais C; Basmaci R; Cohen R; Ouldali N
    Lancet Reg Health Eur; 2024 Sep; 44():101007. PubMed ID: 39139197
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Single Intramuscular Dose of Nirsevimab Reduces Likelihood of Hospitalization Due to RSV in Average-Risk Infants During First Year of Life.
    Ebell MH
    Am Fam Physician; 2024 May; 109(5):477-478. PubMed ID: 38804769
    [No Abstract]   [Full Text] [Related]  

  • 59. Effectiveness of Palivizumab Against Respiratory Syncytial Virus Hospitalization Among Preterm Infants in a Setting With Year-Round Circulation.
    Yeo KT; Yung CF; Khoo PC; Saffari SE; Sng JSP; How MS; Quek BH
    J Infect Dis; 2021 Jul; 224(2):279-287. PubMed ID: 33274362
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of palivizumab on admission to the ICU for respiratory syncytial virus bronchiolitis: a national survey.
    Prais D; Danino D; Schonfeld T; Amir J
    Chest; 2005 Oct; 128(4):2765-71. PubMed ID: 16236953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.